OK Biotech Co., Ltd. manufactures and sells blood glucose meters worldwide. More Details
Excellent balance sheet and fair value.
Share Price & News
How has OK Biotech's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 4155 is less volatile than 75% of TW stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: 4155's weekly volatility (3%) has been stable over the past year.
7 Day Return
TW Medical Equipment
1 Year Return
TW Medical Equipment
Return vs Industry: 4155 underperformed the TW Medical Equipment industry which returned 7% over the past year.
Return vs Market: 4155 underperformed the TW Market which returned 34.2% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is OK Biotech's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 months ago | Simply Wall StOK Biotech Co., Ltd. (TPE:4155) Investors Should Think About This Before Buying It For Its Dividend
5 months ago | Simply Wall StCalculating The Fair Value Of OK Biotech Co., Ltd. (TPE:4155)
5 months ago | Simply Wall StOK Biotech (TPE:4155) Has A Pretty Healthy Balance Sheet
Is OK Biotech undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 4155 (NT$22.05) is trading below our estimate of fair value (NT$30.17)
Significantly Below Fair Value: 4155 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 4155's PE Ratio (22.7x) is in line with the TW Medical Equipment industry average.
PE vs Market: 4155 is poor value based on its PE Ratio (22.7x) compared to the TW market (16.4x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 4155's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 4155 is good value based on its PB Ratio (1.3x) compared to the TW Medical Equipment industry average (2.1x).
How is OK Biotech forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as OK Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has OK Biotech performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 4155 has high quality earnings.
Growing Profit Margin: 4155's current net profit margins (6.6%) are lower than last year (10.3%).
Past Earnings Growth Analysis
Earnings Trend: 4155's earnings have grown by 4.3% per year over the past 5 years.
Accelerating Growth: 4155's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 4155 had negative earnings growth (-34.2%) over the past year, making it difficult to compare to the Medical Equipment industry average (9.5%).
Return on Equity
High ROE: 4155's Return on Equity (4.7%) is considered low.
How is OK Biotech's financial position?
Financial Position Analysis
Short Term Liabilities: 4155's short term assets (NT$1.5B) exceed its short term liabilities (NT$664.1M).
Long Term Liabilities: 4155's short term assets (NT$1.5B) exceed its long term liabilities (NT$427.3M).
Debt to Equity History and Analysis
Debt Level: 4155's debt to equity ratio (30.4%) is considered satisfactory.
Reducing Debt: 4155's debt to equity ratio has reduced from 33.3% to 30.4% over the past 5 years.
Debt Coverage: 4155's debt is not well covered by operating cash flow (1.9%).
Interest Coverage: 4155's interest payments on its debt are well covered by EBIT (14.3x coverage).
What is OK Biotech current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 4155's dividend (6.35%) is higher than the bottom 25% of dividend payers in the TW market (1.94%).
High Dividend: 4155's dividend (6.35%) is in the top 25% of dividend payers in the TW market (5.26%)
Stability and Growth of Payments
Stable Dividend: 4155's dividend payments have been volatile in the past 10 years.
Growing Dividend: 4155's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (140.1%), 4155's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
OK Biotech has no CEO, or we have no data on them.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
OK Biotech Co., Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: OK Biotech Co., Ltd.
- Ticker: 4155
- Exchange: TWSE
- Founded: 2006
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: NT$2.077b
- Shares outstanding: 94.18m
- Website: https://www.okbiotech.com
- OK Biotech Co., Ltd.
- No. 91, Gongdao 5th Road
- Sec. 2
- Hsinchu City
OK Biotech Co., Ltd. manufactures and sells blood glucose meters worldwide. It also provides nebulizers, glucometers, blood sugar meters, blood glucose test strips, and personal sound amplifiers. The compa...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/16 15:35|
|End of Day Share Price||2021/09/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.